- NCIt
- C68701
Loading cancer entity…
Loading cancer entity…
Clinical trials
81 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (21)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01165632 | Fluorine F 18 Fluorodopa-Labeled PET Scan in Planning Surgery and Radiation Therapy in Treating Patients With Newly Diagnosed High- or Low-Grade Malignant Glioma | completed | Early Phase 1 | 24 | Mayo ClinicOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT02186509 | Alisertib and Fractionated Stereotactic Radiosurgery in Treating Patients With Recurrent High Grade Gliomas | completed | Phase 1 | 17 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 30, 2025 |
| clinicaltrials |
| NCT01894061 | NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma | completed | Phase 2 | 25 | Case Comprehensive Cancer CenterOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT00662506 | Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma | completed | Phase 1 / Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2023 | clinicaltrials |
| NCT04657315 | Evaluation of Maximum Tolerated Dose, Safety and Efficiency of MSC11FCD Therapy to Recurrent Glioblastoma Patients(MSC11FCD-GBM) | completed | Phase 1 / Phase 2 | 10 | CHA UniversityOTHER | 1 | Jan 18, 2023 | clinicaltrials |
| NCT01730950 | Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma | completed | Phase 2 | 182 | Radiation Therapy Oncology GroupNETWORK | 1 | Dec 29, 2022 | clinicaltrials |
| NCT00731731 | Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 125 | National Cancer Institute (NCI)NIH | 1 | Aug 4, 2022 | clinicaltrials |
| NCT01062425 | Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma | completed | Phase 2 | 261 | National Cancer Institute (NCI)NIH | 1 | Jul 26, 2022 | clinicaltrials |
| NCT02015819 | Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas | completed | Phase 1 | 16 | City of Hope Medical CenterOTHER | 1 | Oct 20, 2021 | clinicaltrials |
| NCT01051557 | Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma | completed | Phase 1 / Phase 2 | 36 | National Cancer Institute (NCI)NIH | 1 | Jul 19, 2021 | clinicaltrials |
| NCT00052208 | Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 158 | National Cancer Institute (NCI)NIH | 1 | Oct 30, 2020 | clinicaltrials |
| NCT01806675 | 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy | completed | Phase 1 / Phase 2 | 25 | Sanjiv Sam GambhirOTHER | 1 | Oct 3, 2019 | clinicaltrials |
| NCT00423735 | Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma | completed | Phase 2 | 64 | National Cancer Institute (NCI)NIH | 3 | Jul 24, 2019 | clinicaltrials |
| NCT02337426 | Dimethyl Fumarate, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 1 | 12 | Virginia Commonwealth UniversityOTHER | 1 | Jun 28, 2019 | clinicaltrials |
| NCT00902577 | MRI and PET/FMISO In Assessing Tumor Hypoxia in Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Apr 8, 2019 | clinicaltrials |
| NCT01977677 | Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma | completed | Phase 1 / Phase 2 | 30 | Lawrence RechtOTHER | 1 | Oct 23, 2018 | clinicaltrials |
| NCT00329719 | Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma | completed | Phase 1 / Phase 2 | 115 | National Cancer Institute (NCI)NIH | 1 | Oct 16, 2018 | clinicaltrials |
| NCT00433381 | Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma | completed | Phase 2 | 123 | National Cancer Institute (NCI)NIH | 1 | Sep 17, 2018 | clinicaltrials |
| NCT00335764 | Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma | completed | Phase 1 / Phase 2 | 92 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2018 | clinicaltrials |
| NCT01648348 | Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 116 | National Cancer Institute (NCI)NIH | 1 | May 23, 2018 | clinicaltrials |
| NCT01234740 | Bafetinib in Treating Patients With Recurrent High-Grade Glioma or Brain Metastases | completed | Phase 1 | 7 | City of Hope Medical CenterOTHER | 1 | Apr 17, 2018 | clinicaltrials |
| NCT00305864 | Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma | completed | Phase 1 / Phase 2 | 118 | National Cancer Institute (NCI)NIH | 1 | Mar 5, 2018 | clinicaltrials |
| NCT01753713 | Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma | completed | Phase 2 | 33 | Manmeet Ahluwalia, MDOTHER | 1 | Dec 12, 2017 | clinicaltrials |
| NCT01172964 | A Pilot Feasibility Study of Oral 5-Fluorocytosine and Genetically-Modified Neural Stem Cells Expressing E.Coli Cytosine Deaminase for Treatment of Recurrent High Grade Gliomas | completed | Phase 1 | 15 | City of Hope Medical CenterOTHER | 1 | Nov 9, 2017 | clinicaltrials |
| NCT00045708 | A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas | completed | Phase 1 / Phase 2 | 57 | National Cancer Institute (NCI)NIH | 1 | Oct 18, 2017 | clinicaltrials |
| NCT00045110 | Erlotinib in Treating Patients With Recurrent Malignant Glioma or Recurrent or Progressive Meningioma | completed | Phase 1 / Phase 2 | 136 | National Cancer Institute (NCI)NIH | 1 | Aug 17, 2017 | clinicaltrials |
| NCT00980343 | GDC-0449 in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery | completed | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | Aug 16, 2017 | clinicaltrials |
| NCT00540722 | Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme | completed | Phase 2 | 56 | National Cancer Institute (NCI)NIH | 1 | Aug 11, 2017 | clinicaltrials |
| NCT00823797 | Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma | completed | Phase 2 | 45 | University of WashingtonOTHER | 1 | Jul 7, 2017 | clinicaltrials |
| NCT00379080 | Tandutinib in Treating Patients With Recurrent or Progressive Glioblastoma | completed | Phase 1 / Phase 2 | 60 | National Cancer Institute (NCI)NIH | 1 | Apr 7, 2017 | clinicaltrials |
| NCT00459381 | Pazopanib in Treating Patients With Recurrent Glioblastoma | completed | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Mar 15, 2017 | clinicaltrials |
| NCT00085540 | FR901228 in Treating Patients With Recurrent High-Grade Gliomas | completed | Phase 1 / Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Jan 2, 2017 | clinicaltrials |
| NCT00445588 | Erlotinib and Sorafenib in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme | completed | Phase 2 | 56 | National Cancer Institute (NCI)NIH | 1 | Apr 27, 2016 | clinicaltrials |
| NCT00499473 | Sunitinib in Treating Patients With Recurrent Malignant Gliomas | completed | Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Feb 29, 2016 | clinicaltrials |
| NCT00085254 | Cilengitide, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 112 | National Cancer Institute (NCI)NIH | 1 | Feb 25, 2016 | clinicaltrials |
| NCT00369590 | VEGF Trap in Treating Patients With Recurrent Malignant Gliomas That Did Not Respond to Temozolomide | completed | Phase 2 | 58 | National Cancer Institute (NCI)NIH | 1 | Oct 2, 2015 | clinicaltrials |
| NCT01119599 | RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma | completed | Phase 1 | 22 | National Cancer Institute (NCI)NIH | 1 | Sep 29, 2015 | clinicaltrials |
| NCT00112736 | Erlotinib and Temsirolimus in Treating Patients With Recurrent Malignant Glioma | completed | Phase 1 / Phase 2 | 69 | National Cancer Institute (NCI)NIH | 1 | Jun 15, 2015 | clinicaltrials |
| NCT00004146 | Carboxyamidotriazole + RT in Treating Patients Newly Diagnosed Supratentorial GBM | completed | Phase 2 | 55 | National Cancer Institute (NCI)NIH | 1 | May 8, 2015 | clinicaltrials |
| NCT00049387 | Tipifarnib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma | completed | Phase 1 | 19 | National Cancer Institute (NCI)NIH | 1 | Apr 15, 2015 | clinicaltrials |
| NCT00979862 | Cediranib Maleate and Cilengitide in Treating Patients With Progressive or Recurrent Glioblastoma | completed | Phase 1 | 47 | National Cancer Institute (NCI)NIH | 1 | Apr 15, 2015 | clinicaltrials |
| NCT01131234 | Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors | completed | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Dec 23, 2014 | clinicaltrials |
| NCT02227901 | Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 1 | 19 | National Cancer Institute (NCI)NIH | 1 | Dec 23, 2014 | clinicaltrials |
| NCT00093613 | Sorafenib in Treating Patients With Recurrent or Progressive Malignant Glioma | completed | Phase 1 | 47 | National Cancer Institute (NCI)NIH | 1 | May 30, 2014 | clinicaltrials |
| NCT00650923 | Aflibercept, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma Multiforme, Gliosarcoma, or Other Malignant Glioma | completed | Phase 1 | 61 | National Cancer Institute (NCI)NIH | 1 | May 30, 2014 | clinicaltrials |
| NCT00238303 | Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme | completed | Phase 2 | 103 | National Cancer Institute (NCI)NIH | 1 | May 23, 2014 | clinicaltrials |
| NCT00641706 | Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme | completed | Phase 2 | 44 | National Cancer Institute (NCI)NIH | 1 | May 14, 2014 | clinicaltrials |
| NCT00305656 | AZD2171 in Treating Patients With Recurrent Glioblastoma Multiforme | completed | Phase 2 | 31 | National Cancer Institute (NCI)NIH | 1 | Aug 22, 2013 | clinicaltrials |
| NCT00039494 | Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors | completed | Phase 2 | 171 | National Cancer Institute (NCI)NIH | 1 | Aug 2, 2013 | clinicaltrials |
| NCT00016328 | CCI-779 in Treating Patients With Recurrent Glioblastoma Multiforme | completed | Phase 2 | 33 | National Cancer Institute (NCI)NIH | 1 | Jul 18, 2013 | clinicaltrials |
Data updated 22 days agoSource updated Sep 2, 2025source: clinicaltrials